With a market cap of $9.3 billion, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development of messenger RNA (mRNA) therapeutics and vaccines. Known for its COVID-19 vaccine ...

and Furuichi et al., revealed that certain viral and eukaryotic mRNAs have a cap — a methylated guanosine residue linked to the 5′ end of mRNA through an inverted 5′ to 5′ triphosphate bridge.

kinetoplast mRNA editing) and under conditions of cellular stress (e.g., virus infection, unfolded protein response). RNA cleavage can occur either: (i) by a transesterification mechanism that yields ...

The popularity of mRNA-based therapeutics has surged over the past few years. To ensure the safety of these treatments, scientists need to analyze the characteristics of the manufactured molecules, ...

Alternatively, researchers can also modify the chemical structure of the mRNA cap found at the molecule’s 5’ end. The naturally-occurring cap structure typical in mammalian cells has a ...

Overview: CureVac N.V. is a biopharmaceutical company specializing in the development of transformative mRNA-based medicines, with a market cap of approximately $715.56 million. Operations ...

South African global pharmaceutical giant Aspen Pharmacare has found itself caught in Trump tariff-related market volatility, as it witnessed R22 billion being wiped off its JSE market capitalisation ...

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also ... Shares in DBV jumped nearly 56 percent to US$5.41 on January 10. The next big boost for DBV ...

Vaccines using mRNA are currently being studied for a wide range of diseases, including cancer, cardiovascular disease, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The mRNA cap structure is an important point of consideration for the immunogenicity of your mRNA-based product. Whereas legacy cap analogs produce a Cap0 structure and are recognized by the immune ...